There are 702 resources available
Q&A and discussion
Session: Mini Oral Session 2
Resources:
Webcast
242MO - Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201
Presenter: Kristen Ciombor
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited discussant abstracts 7MO, 8MO and 242MO
Presenter: Juan Manuel Ramon O'Connor
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and discussion
Session: Mini Oral session 2
Resources:
Webcast
Welcome and introduction
Presenter: Sylvie Lorenzen
Session: BeiGene - Advances in upper GI immunotherapy: What’s new on the horizon?
Resources:
Webcast
Oesophageal squamous cell carcinoma: Treatment landscape, clinical guidelines and immunotherapy
Presenter: Filippo Pietrantonio
Session: BeiGene - Advances in upper GI immunotherapy: What’s new on the horizon?
Resources:
Webcast
A focus on recent data for PD-1 inhibitors in first- and second-line treatment of oesophageal squamous cell carcinoma
Presenter: Jean-Philippe Metges
Session: BeiGene - Advances in upper GI immunotherapy: What’s new on the horizon?
Resources:
Webcast
New era for pathologists: PD-L1 expression in upper GI cancers
Presenter: Matteo Fassan
Session: BeiGene - Advances in upper GI immunotherapy: What’s new on the horizon?
Resources:
Webcast
Management and individualised approaches for patients with gastric and gastro-oesophageal junction adenocarcinoma
Presenter: Sylvie Lorenzen
Session: BeiGene - Advances in upper GI immunotherapy: What’s new on the horizon?
Resources:
Webcast
Novel immunological combinations in first-line treatment of gastric and gastro-oesophageal junction adenocarcinoma
Presenter: Maria Alsina Maqueda
Session: BeiGene - Advances in upper GI immunotherapy: What’s new on the horizon?
Resources:
Webcast